EIF2AK2 Mouse monoclonal Antibody IgG1
Fig1: Western blot analysis of EIF2AK2 on human EIF2AK2 recombinant protein using anti- EIF2AK2 antibody at 1/1,000 dilution.
Fig2: Western blot analysis of EIF2AK2 on HEK293 (1) and EIF2AK2-hIgGFc transfected HEK293 (2) cell lysateusing using anti-FTL antibody at 1/1,000 dilution.
Fig3: Western blot analysis of EIF2AK2 on cells lysates using anti- EIF2AK2 antibody at 1/1,000 dilution.
Positive control: Line1: A431 Line2: THP-1 Line3: MCF-7 Line4: PC-12
Host Species; Species ReactivityMouse; Human
Application SummaryWB, IHC, FC
Purification; FormulationProA affinity purified; 1*TBS (pH7.4), 1%BSA, Preservative: 0.05% Sodium Azide.; Liquid form.
ALTnamesCasein kinase II subunit beta, Phosvitin, Protein G5a
BackgroundInterferon-inducible RNA-dependent protein serine/threonine kinase, PKR, is variously designated in earlier literature as DAI, dsJ, PI kinase, p65, p67 or TIK for the mouse kinase; and p68, eIF-2α protein kinase or p69 for the human kinase. The PKR kinase substrate is the α subunit of protein synthesis initiation factor eIF-2. Phosphorylation of eIF-2α on serine-51 results in inhibition of translation. Molecular cDNA clones have been isolated from both human and mouse cells. The serine/threonine kinase catalytic domains map to the carboxy terminal half of the protein while the RNA-binding domains are located in the amino terminal region. Three kinds of regulation of PKR enzymatic activity have been described. These include transcriptional regulation in response to interferon, an autoregulatory mechanism controlling PKR expression at the level of translation and post-translational regulation by RNA-mediated autophosphorylation.(EM1706-35)